Treats Attention-Deficit/Hyperactivity Disorder (ADHD). ANDA 202682, held by Hetero Labs. Atomoxetine Hydrochloride.
As of Nov 21, 2026, ANDA 202682 (Atomoxetine Hydrochloride), held by Hetero Labs, was first approved by FDA on Mar 11, 2021, with 1 approved supplement and 0 published complete response letters.
Atomoxetine capsule is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). 1.1 Attention-Deficit/Hyperactivity Disorder (ADHD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 11, 2021 | Original application | Approved | None posted |
| Atomoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 18MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 25MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 40MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 60MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 80MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| Atomoxetine HydrochlorideEQ 100MG BASE · capsule;oral | Atomoxetine Hydrochloride | Rx |
| May 8, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 11, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters